The Use of Levofloxacin for the Treatment of Acute Exacerbation of Chronic Bronchitis (Interview with Prof. Hartmut Lode)
Question
| AECB – Defining the diagnosis |
| Q01 | Defining AECB |
| Q02 | Epidemiological profile of AECB |
| Antimicrobial therapy for AECB |
| Q03 | Benefits of antimicrobial therapy |
| Q04 | Treatment with antibiotics |
| Q05 | Considerations when choosing antimicrobials |
| Causes of AECB |
| Q06 | Major causes of AECB |
| Q07 | Etiological pathogens by GOLD severity stage |
| Therapeutic guidelines and considerations |
| Q08 | Activity profiles of antibiotics by class |
| Q09 | Therapeutic guidelines for AECB |
| Q10 | The role of older antibiotics |
| Q11 | Therapeutic considerations when treating AECB |
| Q12 | Fluoroquinolones for AECB |
| AECB clinical trials and recent results |
| Q13 | Outcome measures for AECB clinical trials |
| Q14 | Levofloxacin vs. clarithromycin study overview |
| Q15 | Study results |
| Q16 | Cost-effectiveness of fluoroquinolones for AECB |
| Safety, treatment duration and concerns |
| Q17 | Safety considerations of antibiotic treatment |
| Q18 | Treatment duration |
| Q19 | Remaining problems for physicians treating AECB |
| References |
LATEST TOPICS
RELATED ARTICLES
